Rx License-Rx

TAB-4306

Single domain CD4, HIV-1 Antibodies, and Fusion Proteins for treatment of HIV

Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy. sCD4 is also known to interact with class II major histocompatibility complex (MHCII) and, at low concentrations, could enhance HIV-1 infectivity. NCI researchers developed highly soluble, stable single-domain sCD4 with increased neutralizing activity and decreased non-specific binding compared to two-domain sCD4. This invention describes this single-domain sCD4, designated D1, and mutants such as mD1.22 which is highly soluble and stable with good neutralizing activity without measurable interaction with MHCII. The inventors have previously described a novel human domain antibody against HIV-1, designated m36. Due to its small...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Infectious Disease

Indication: HIV

Modality: Biologic

Focus tags: Infectious Disease, Immunology

Technology tags: Biologic, Small Molecule

Mechanism:

Development stage: Early / Discovery

Patent status: Abandoned; Expired; Issued; Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Infectious Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be early / discovery and is associated with National Institutes of Health. The practical first use case is HIV. Public description: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells. Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have.

What is exciting

Early enough to shape the whole strategy: Because the asset is still early, a licensee can choose the best indication, data package, CRO path, and partnering story before heavy spend.

The License-Rx pivot is the real unlock: The exciting version is not just the university pitch; it is the focused path: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Negatives / diligence concerns

Very early technical risk: The asset likely still needs independent replication, translational validation, and a clear go/no-go experiment before a serious license fee is justified.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Infectious Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets GSK — Vaccines and anti-infective infrastructure. Pfizer — Hospital, anti-infective, and vaccine commercial reach. Johnson & Johnson — Pathogen-focused development and global health channels.

Development Strategy to Increase PoS

First indication: HIV

Study design: One decisive preclinical or analytical validation package with a hard go/no-go threshold.

Key experiments Validate the AI-optimized pivot: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed with repositioning: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Target a resistant-pathogen niche with regulatory pull instead of a broad anti-infective launch

Best next experiment: Run the smallest independent study that validates: Run pathogen-panel susceptibility, resistance mapping, and one translational model before any broad tox spend.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.